Compare argenx SE with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.90%
- Poor long term growth as Operating profit has grown by an annual rate 31.00% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.81
2
With ROE of 18.15%, it has a Very Expensive valuation with a 7.88 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.71%
0%
13.71%
6 Months
9.72%
0%
9.72%
1 Year
32.55%
0%
32.55%
2 Years
63.43%
0%
63.43%
3 Years
72.63%
0%
72.63%
4 Years
111.88%
0%
111.88%
5 Years
190.19%
0%
190.19%
argenx SE for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
148.85%
EBIT Growth (5y)
31.00%
EBIT to Interest (avg)
-73.64
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.35
Tax Ratio
1.83%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
12.99%
ROE (avg)
2.90%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
7.88
EV to EBIT
53.39
EV to EBITDA
51.87
EV to Capital Employed
18.40
EV to Sales
12.39
PEG Ratio
0.98
Dividend Yield
NA
ROCE (Latest)
34.47%
ROE (Latest)
18.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,680.30
2,024.80
81.76%
Operating Profit (PBDIT) excl Other Income
902.70
-42.90
2,204.20%
Interest
3.60
2.30
56.52%
Exceptional Items
10.30
20.90
-50.72%
Consolidate Net Profit
1,144.80
770.10
48.66%
Operating Profit Margin (Excl OI)
238.50%
-29.20%
26.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 81.76% vs 78.51% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 48.66% vs 382.19% in Dec 2024
About argenx SE 
argenx SE
Pharmaceuticals & Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.






